GILEAD SCIENCES, INC. Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31)
GILEAD SCIENCES, INC. (GILD) reported Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) of -$24.61 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease · last filed 2012-05-04
- GILEAD SCIENCES, INC. other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was -$24.61M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $117.74M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-06-30 was -$32.10M, a 130.24% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-03-31 was -$132.09M, a 248.04% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2010 was $45.09M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2009 was -$55.46M, a 183.08% decline from fiscal 2008.
- GILEAD SCIENCES, INC. other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2008 was $66.75M.
| Period end | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | -$24.61M 10-Q · filed 2012-05-04 | |||
| 2011-09-30 | $117.74M 10-Q · filed 2011-11-04 | $85.64M derived: sum of 2 quarters · filed 2011-11-04 | -$46.45M 10-Q · filed 2011-11-04 | -$14.61M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | -$32.10M 10-Q · filed 2011-08-05 | -$164.19M 10-Q · filed 2011-08-05 | -$132.35M derived: sum of 3 quarters · filed 2012-05-04 | -$314.49M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | -$132.09M 10-Q · filed 2012-05-04 | -$100.25M derived: sum of 2 quarters · filed 2012-05-04 | -$282.39M derived: sum of 3 quarters · filed 2012-05-04 | -$176.24M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | $31.84M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | -$150.30M derived: sum of 2 quarters · filed 2011-11-04 | -$44.15M derived: sum of 3 quarters · filed 2011-11-04 | $45.09M 10-K · filed 2011-02-28 |
| 2010-09-30 | -$182.14M 10-Q · filed 2011-11-04 | -$75.99M derived: sum of 2 quarters · filed 2011-11-04 | $13.24M 10-Q · filed 2011-11-04 | $38.23M derived: sum of 4 quarters · filed 2011-11-04 |
| 2010-06-30 | $106.15M 10-Q · filed 2011-08-05 | $195.38M 10-Q · filed 2011-08-05 | $220.36M derived: sum of 3 quarters · filed 2011-08-05 | $157.87M derived: sum of 4 quarters · filed 2011-08-05 |
| 2010-03-31 | $89.23M 10-Q · filed 2011-05-09 | $114.21M derived: sum of 2 quarters · filed 2011-05-09 | $51.72M derived: sum of 3 quarters · filed 2011-05-09 | -$36.63M derived: sum of 4 quarters · filed 2011-05-09 |
| 2009-12-31 | $24.98M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | -$37.51M derived: sum of 2 quarters · filed 2011-02-28 | -$125.86M derived: sum of 3 quarters · filed 2011-02-28 | -$55.46M 10-K · filed 2011-02-28 |
| 2009-09-30 | -$62.49M 10-Q · filed 2010-11-08 | -$150.84M derived: sum of 2 quarters · filed 2010-11-08 | -$80.44M 10-Q · filed 2010-11-08 | |
| 2009-06-30 | -$88.35M 10-Q · filed 2010-08-09 | -$17.95M 10-Q · filed 2010-08-09 | ||
| 2008-12-31 | $66.75M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |